1-[[amino(pyrazin-2-yl)methylidene]amino]-3-cyclohexylthiourea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-[[amino(pyrazin-2-yl)methylidene]amino]-3-cyclohexylthiourea
• 化学式: C₁₂H₁₈N₆S
• 分子量: 278.381
• InChiKey: SKQASIKSJUBHLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  bismuth(III) chloride 、 水 、 1-[[amino(pyrazin-2-yl)methylidene]amino]-3-cyclohexylthiourea 以 甲醇 为溶剂， 反应 28.0h， 以71%的产率得到
  参考文献：
  名称：

  Bismuth(III) complexes with pyrazineformamide thiosemicarbazones: Investigation on the antimicrobial and cytotoxic effects

  摘要：

  Complexes [Bi(PzAm4DH)Cl-2] (1), [Bi(PzAm4M)Cl-2] (2), [Bi(PzAm4E)Cl-2] (3), [Bi(PzAm4Cy)Cl-2]center dot 3H(2)O (4) and [Bi(PzAm4Ph)Cl-2] (5) were prepared with 2-pyrazineformamide- (HPzAm4DH, L1), N(4)-methyl-2-pyrazineformamide- (HPzAm4M, L2), N(4)-ethyl-2-pyrazineformamide- (HPzAm4E, L3), N(4)-cyclohexyl-2-pyrazineformamide (HPzAm4Cy, L4) and N(4)-phenyl-2-pyrazineformamide (HPzAm4Ph, L5) thiosemicarbazones. L4 crystallized from methanol in monoclinic crystal system. All compounds were assayed for their cytotoxicity against SF-295 (glioblastoma multiforme) and HCT-116 (colon adenocarcinoma) human tumor cell lines and Mycobacterium tuberculosis H37Rv ATCC 27294 strain. Complexes 1-5 proved to have poor activity against the tumor cells at 5 mu g/mL, whereas for complexes 4 and 5, coordination to Bi(III) was an effective strategy to increase the antimycobacterial activity of the thiosemicarbazones L4 and L5. (C) 2020 Published by Elsevier Ltd.

  DOI：

  10.1016/j.poly.2020.114709
• 作为产物：
  描述：

  环己基异硫氰酸脂 在 sodium 、 肼 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 52.5h， 生成 1-[[amino(pyrazin-2-yl)methylidene]amino]-3-cyclohexylthiourea
  参考文献：
  名称：

  Bismuth(III) complexes with pyrazineformamide thiosemicarbazones: Investigation on the antimicrobial and cytotoxic effects

  摘要：

  Complexes [Bi(PzAm4DH)Cl-2] (1), [Bi(PzAm4M)Cl-2] (2), [Bi(PzAm4E)Cl-2] (3), [Bi(PzAm4Cy)Cl-2]center dot 3H(2)O (4) and [Bi(PzAm4Ph)Cl-2] (5) were prepared with 2-pyrazineformamide- (HPzAm4DH, L1), N(4)-methyl-2-pyrazineformamide- (HPzAm4M, L2), N(4)-ethyl-2-pyrazineformamide- (HPzAm4E, L3), N(4)-cyclohexyl-2-pyrazineformamide (HPzAm4Cy, L4) and N(4)-phenyl-2-pyrazineformamide (HPzAm4Ph, L5) thiosemicarbazones. L4 crystallized from methanol in monoclinic crystal system. All compounds were assayed for their cytotoxicity against SF-295 (glioblastoma multiforme) and HCT-116 (colon adenocarcinoma) human tumor cell lines and Mycobacterium tuberculosis H37Rv ATCC 27294 strain. Complexes 1-5 proved to have poor activity against the tumor cells at 5 mu g/mL, whereas for complexes 4 and 5, coordination to Bi(III) was an effective strategy to increase the antimycobacterial activity of the thiosemicarbazones L4 and L5. (C) 2020 Published by Elsevier Ltd.

  DOI：

  10.1016/j.poly.2020.114709

文献信息

• Bismuth(III) complexes with pyrazineformamide thiosemicarbazones: Investigation on the antimicrobial and cytotoxic effects
  作者：Jéssica C.L. Almeida、Raquel S. Amim、Claudia Pessoa、Maria C.S. Lourenço、Isolda C. Mendes、Josane A. Lessa

  DOI：10.1016/j.poly.2020.114709

  日期：2020.10

  Complexes [Bi(PzAm4DH)Cl-2] (1), [Bi(PzAm4M)Cl-2] (2), [Bi(PzAm4E)Cl-2] (3), [Bi(PzAm4Cy)Cl-2]center dot 3H(2)O (4) and [Bi(PzAm4Ph)Cl-2] (5) were prepared with 2-pyrazineformamide- (HPzAm4DH, L1), N(4)-methyl-2-pyrazineformamide- (HPzAm4M, L2), N(4)-ethyl-2-pyrazineformamide- (HPzAm4E, L3), N(4)-cyclohexyl-2-pyrazineformamide (HPzAm4Cy, L4) and N(4)-phenyl-2-pyrazineformamide (HPzAm4Ph, L5) thiosemicarbazones. L4 crystallized from methanol in monoclinic crystal system. All compounds were assayed for their cytotoxicity against SF-295 (glioblastoma multiforme) and HCT-116 (colon adenocarcinoma) human tumor cell lines and Mycobacterium tuberculosis H37Rv ATCC 27294 strain. Complexes 1-5 proved to have poor activity against the tumor cells at 5 mu g/mL, whereas for complexes 4 and 5, coordination to Bi(III) was an effective strategy to increase the antimycobacterial activity of the thiosemicarbazones L4 and L5. (C) 2020 Published by Elsevier Ltd.